TY - JOUR
T1 - Gastric Adenocarcinoma
T2 - An Update on Genomics, Immune System Modulations, and Targeted Therapy
AU - Lee, Jeeyun
AU - Bass, Adam J.
AU - Ajani, Jaffer A.
PY - 2016
Y1 - 2016
N2 - Gastric adenocarcinoma (GAC) is a global health burden on all societies, and it was the third-leading cause of cancer-related mortality in 2012, causing 723,000 deaths worldwide. The prognosis of patients with metastatic GAC remains poor, with a median overall survival of less than 1 year in patients treated with currently available therapies. A limited number of therapeutic agents is currently available. Recent additions to the armamentarium include trastuzumab and ramucirumab, which have shown some survival advantage when added to cytotoxic(s). Genomic analyses have defined various genotypes of GACs. The novel genomic knowledge can lead to discovery of novel targets and novel therapeutic agents. In this update, we focus on the current genomic data, targeted therapies including immune system modulators, and expand on HER2/neu testing and the use of agents against this target. Several other facets of GAC and its therapy are not to be included in this review but have been discussed elsewhere.
AB - Gastric adenocarcinoma (GAC) is a global health burden on all societies, and it was the third-leading cause of cancer-related mortality in 2012, causing 723,000 deaths worldwide. The prognosis of patients with metastatic GAC remains poor, with a median overall survival of less than 1 year in patients treated with currently available therapies. A limited number of therapeutic agents is currently available. Recent additions to the armamentarium include trastuzumab and ramucirumab, which have shown some survival advantage when added to cytotoxic(s). Genomic analyses have defined various genotypes of GACs. The novel genomic knowledge can lead to discovery of novel targets and novel therapeutic agents. In this update, we focus on the current genomic data, targeted therapies including immune system modulators, and expand on HER2/neu testing and the use of agents against this target. Several other facets of GAC and its therapy are not to be included in this review but have been discussed elsewhere.
UR - http://www.scopus.com/inward/record.url?scp=85014084462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014084462&partnerID=8YFLogxK
U2 - 10.14694/EDBK_159091
DO - 10.14694/EDBK_159091
M3 - Review article
C2 - 27249691
AN - SCOPUS:85014084462
SN - 1548-8756
VL - 35
SP - 104
EP - 111
JO - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting
JF - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting
ER -